DDInter460 DDInter178
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Cytarabine {u} (Compound) resembles {v} (Compound) Regadenoson
Cytarabine {u} (Compound) resembles {v} (Compound) Nelarabine
Cytarabine {u} (Compound) treats {v} (Disease) hematologic cancer
Cytarabine {u} (Compound) binds {v} (Gene) POLB
Cytarabine {u} (Compound) upregulates {v} (Gene) TICAM1
Cytarabine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleic Acid Synthesis Inhibitors
Cytarabine {u} (Compound) downregulates {v} (Gene) KIF4A
Cytarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Cytarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Cytarabine (Compound) resembles Regadenoson (Compound)
Cytarabine (Compound) resembles Nelarabine (Compound)
Cytarabine (Compound) treats hematologic cancer (Disease)
Cytarabine (Compound) binds POLB (Gene)
Cytarabine (Compound) upregulates TICAM1 (Gene)
Cytarabine (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class)
Cytarabine (Compound) downregulates KIF4A (Gene)
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin